Cambridge Equities, LP - 23 Feb 2026 SCHEDULE 13D/A Report for ImmunityBio, Inc. Common Stock, par value $0.0001 per share (IBRX)

Filing Manager
Cambridge Equities, LP
Reporting Manager
Patrick Soon-Shiong
Security
ImmunityBio, Inc. Common Stock, par value $0.0001 per share
Symbol
IBRX
Shares outstanding
1,124,549,707 shares
Disclosed Ownership
745,576,456 shares
Ownership
66%
Form type
SCHEDULE 13D/A
Filing time
25 Feb 2026, 21:51:53 UTC
Date of event
23 Feb 2026
Previous filing
10 Nov 2025
SEC
View on sec.gov

Reporting Managers (6)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Cambridge Equities, LP 26% 261,705,814 0 261,705,814 /s/ Charles Kenworthy Charles Kenworthy, Manager of MP 13 Ventures, LLC, the General Partner of Cambridge Equities, LP 0001629222
MP 13 Ventures, LLC 26% 261,705,814 0 261,705,814 /s/ Charles Kenworthy Charles Kenworthy, Manager 0001629186
NantWorks, LLC 9.6% 98,535,253 0 98,535,253 /s/ Robert Morse Robert Morse, CFO of NantWorks, LLC 0001675760
Nant Capital, LLC 30% 339,465,529 0 339,465,529 /s/ Charles Kenworthy Charles Kenworthy, Manager of Nant Capital, LLC 0001675758
California Capital Equity, LLC 10% 106,511,412 0 106,511,412 /s/ Charles Kenworthy Charles Kenworthy, Manager of California Capital Equity, LLC 0001517764
Patrick Soon-Shiong 66% 745,576,456 32,275,375 713,301,081 /s/ Patrick Soon-Shiong Patrick Soon-Shiong 0001189020